Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier P Gisbert

Showing results (351-360 of 567) with videos related to

Pageof 57
Sort By:
United European Gastroenterology Journal|April 19, 2016
Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for Esophagitis in Spain: A cross-sectional study)Núria Piqué, Marta Ponce, Vicente Garrigues, et al.
European Journal of Gastroenterology & Hepatology|April 14, 2020
The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 SurveyGabriele Dragoni, Nik Ding, Krisztina B Gecse, et al.
International Journal of Molecular Sciences|January 25, 2025
Proteomic Profiling of Extracellular Vesicles in Inflammatory Bowel DiseasesMontse Baldán-Martín, Mikel Azkargorta, Ainhoa Lapitz, et al.
Journal of Crohn'S & Colitis|August 18, 2023
Adalimumab Clearance, Rather Than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and EndoscopicallyEmily K Wright, Maria Chaparro, Paolo Gionchetti, et al.
Scientific Reports|October 23, 2020
Serum adipokines as non-invasive biomarkers in Crohn's diseaseLorena Ortega Moreno, Ancor Sanz-Garcia, Marina J Fernández de la Fuente, et al.
Hepato-Gastroenterology|August 12, 2010
Can systemic cytokines predict relapse of inflammatory bowel disease?Valle García-Sánchez, Raúl González, Eva Iglesias-Flores, et al.
Gastroenterologia Y Hepatologia|July 13, 2025
EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-α as first- or second-line biologic treatment among patients with ulcerative colitisFrancesc Casellas, Ana Gutiérrez-Casbas, Cristina Rodríguez, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 21, 2007
Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based studyFrancesc Balaguer, Sergi Castellví-Bel, Antoni Castells, et al.
Molecular Nutrition & Food Research|April 23, 2021
Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal TractSamuel Fernández-Tomé, Pedro Indiano-Romacho, Irene Mora-Gutiérrez, et al.
Journal of Clinical Gastroenterology|May 19, 2009
Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's diseaseCarlos Taxonera, Luis Rodrigo, Francesc Casellas, et al.
Pageof 57

Showing results (351-360 of 567) with videos related to

Sort By:
Pageof 57
United European Gastroenterology Journal|April 19, 2016
Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for Esophagitis in Spain: A cross-sectional study)Núria Piqué, Marta Ponce, Vicente Garrigues, et al.
European Journal of Gastroenterology & Hepatology|April 14, 2020
The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 SurveyGabriele Dragoni, Nik Ding, Krisztina B Gecse, et al.
International Journal of Molecular Sciences|January 25, 2025
Proteomic Profiling of Extracellular Vesicles in Inflammatory Bowel DiseasesMontse Baldán-Martín, Mikel Azkargorta, Ainhoa Lapitz, et al.
Journal of Crohn'S & Colitis|August 18, 2023
Adalimumab Clearance, Rather Than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and EndoscopicallyEmily K Wright, Maria Chaparro, Paolo Gionchetti, et al.
Scientific Reports|October 23, 2020
Serum adipokines as non-invasive biomarkers in Crohn's diseaseLorena Ortega Moreno, Ancor Sanz-Garcia, Marina J Fernández de la Fuente, et al.
Hepato-Gastroenterology|August 12, 2010
Can systemic cytokines predict relapse of inflammatory bowel disease?Valle García-Sánchez, Raúl González, Eva Iglesias-Flores, et al.
Gastroenterologia Y Hepatologia|July 13, 2025
EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-α as first- or second-line biologic treatment among patients with ulcerative colitisFrancesc Casellas, Ana Gutiérrez-Casbas, Cristina Rodríguez, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 21, 2007
Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based studyFrancesc Balaguer, Sergi Castellví-Bel, Antoni Castells, et al.
Molecular Nutrition & Food Research|April 23, 2021
Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal TractSamuel Fernández-Tomé, Pedro Indiano-Romacho, Irene Mora-Gutiérrez, et al.
Journal of Clinical Gastroenterology|May 19, 2009
Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's diseaseCarlos Taxonera, Luis Rodrigo, Francesc Casellas, et al.
Pageof 57